^
    4d
    BGB-A317-290-LTE1: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies (clinicaltrials.gov)
    P3, N=300, Enrolling by invitation, BeiGene | Trial completion date: Aug 2024 --> Dec 2026 | Trial primary completion date: Aug 2024 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    temozolomide • Lenvima (lenvatinib) • Tevimbra (tislelizumab) • Fruzaqla (fruquintinib) • Partruvix (pamiparib) • zanidatamab (ZW25) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445 • LBL-007 • surzebiclimab (BGB-A425)
    4ms
    BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=203, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Sep 2024 | Trial primary completion date: May 2025 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • BGB-A445
    4ms
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=400, Recruiting, BeiGene | N=200 --> 400
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab) • albumin-bound paclitaxel • pemetrexed • BGB-15025 • BGB-A445 • LBL-007
    6ms
    A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    docetaxel • Tevimbra (tislelizumab) • Cyramza (ramucirumab) • sitravatinib (MGCD516) • BGB-15025 • BGB-A445
    8ms
    A Phase 1 (Ph1) Study of the OX40 Agonist, BGB-A445, With or Without Tislelizumab, an Anti-PD-1 Monoclonal Antibody (mAb), in Patients With Advanced Solid Tumors (COSA 2023)
    BGB-A445 ± tislelizumab was well-tolerated across all doses in patients with advanced solid tumors and demonstrated preliminary antitumor activity. The dose-expansion part is ongoing in patients with NSCLC and HNSCC.
    Clinical • P1 data • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Tevimbra (tislelizumab) • BGB-A445
    11ms
    BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=250, Recruiting, BeiGene | N=360 --> 250 | Trial completion date: Sep 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> May 2025
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab) • BGB-A445
    12ms
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=200, Recruiting, BeiGene | Not yet recruiting --> Recruiting | N=300 --> 200 | Trial completion date: Nov 2025 --> Jul 2025 | Trial primary completion date: Nov 2025 --> Jul 2025
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007
    over1year
    A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=300, Not yet recruiting, BeiGene
    New P2 trial • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab) • albumin-bound paclitaxel • pemetrexed • BGB-A445 • LBL-007